IONIS PHARMACEUTICALS INC (IONS) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15
	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K
Revenue:
Revenue	587.4	810.5	729.3	1,122.6	599.7	514.2	372.8	283.7
Revenue growth	-27.5%	11.1%	-35.0%	87.2%	16.6%	37.9%	31.4%	32.5%
Expenses:
Cost of sales	14.1	10.8	11.9	4.4	1.8
Research, development and patent	833.1	643.5	535.1	465.7	414.6	374.6	344.3	322.3
Selling, general and administrative	150.3	186.3	354.3	286.6	244.6	108.5	48.6	37.2
Total operating expenses	997.6	840.6	901.3	756.7	661.0	483.1
Loss from operations	-410.2	-30.2	-172.1	365.9	-61.4	31.0	-20.2	-75.8
Operating margin	-69.8%	-3.7%	-23.6%	32.6%	-10.2%	6.0%	-5.4%	-26.7%

Other income (expense):
Investment income	25.3	10.0	30.6	52.0	30.4	8.2	5.5	4.4
Interest expense	-8.1	-9.3	-9.5	-12.4	-44.8	-44.8	-38.8	-36.7
Gain (loss) on investments	-7.3	10.1	16.5	0.2	-0.2
Other income (expense)	-7.3	-9.8	-0.1	-0.7	-0.2	-3.5
Loss before income tax expense	-258.0	-29.1	-134.6	338.8
Income tax expense	-11.7	0.6	-345.2	-51.5	291.1	6.0	-2.9	-0.4
Net loss	-269.7	-28.6	-444.3	278.1	273.7	0.3	-60.4	-88.3

Basic net loss per share (in dollars per share)	($1.90)	($0.20)	($3.18)	$2.00	$2.09	$0.15	($0.50)	($0.74)
Diluted net loss per share (in dollars per share)	($1.90)	($0.20)	($3.18)	$1.90	$2.07	$0.15	($0.50)	($0.74)

Shares used in computing basic net loss per share (in shares)	141.8	141.0	139.6	140.0	132.3	124.0	120.9	119.7
Shares used in computing diluted net loss per share (in shares)	141.8	141.0	139.6	153.2	134.1	126.1	120.9	119.7